Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Hematology | Musculoskeletal
Search Medical Condition
Post-essential Thrombocythemia Myelofibrosis Clinical Trials
A listing of Post-essential Thrombocythemia Myelofibrosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (9) clinical trials
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
PRIMARY OBJECTIVE: To compare the rate of disease-free survival (DFS) at 1 year post hematopoietic stem cell transplant (HSCT) in patients undergoing HSCT treated on this successor Thomas Jefferson University (TJU) 2 Step reduced intensity conditioning (RIC) haploidentical regimen and compare it with that of the initial 2 Step RIC ...
Durvalumab in Treating Patients With Primary Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
PRIMARY OBJECTIVES: I. To determine the safety profile of anti-programmed cell death 1 ligand 1 (PDL1) therapy in patients with myelofibrosis. SECONDARY OBJECTIVES: I. Changes in MF symptom burden. II. Changes in spleen size. III. Blood and/or bone marrow samples. TERTIARY OBJECTIVES: I. To determine the rate of lymphocyte subset ...
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
PRIMARY OBJECTIVES: I. To determine the efficacy of the combination of RUX (ruxolitinib phosphate) with AZA (azacytidine) in patients with myelofibrosis (MF) (primary myelofibrosis, post polycythemia vera myelofibrosis, or post essential thrombocythemia myelofibrosis [PMF, post- PV MF, or post - ET MF]) in achieving objective improvements in disease status. II. ...
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
The researchers propose a Simon-two stage design for this study. The researchers will test pembrolizumab at the FDA approved dose (in head and neck cancer) of 200mg dose administered via intravenous infusion over 30 minutes given every 3 weeks. Nine patients will be enrolled in the first stage of the ...
IMG-7289 in Patients With Myelofibrosis
This is a Phase 1 open label study of an orally administered LSD1 inhibitor, IMG-7289, in patients with myelofibrosis. This study investigates the following: The safety and tolerability of IMG-7289 The pharmacokinetics of IMG-7289 The pharmacodynamic effect of IMG-7289
KRT-232 in Subjects With PMF Post-PV MF or Post-ET MF Who Have Failed a JAK Inhibitor
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF. This study is a global, open-label Phase 2 study to ...
An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS Intermediate or High-Risk Primary Myelofibrosis Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
This is Single-Arm, Open-Label Efficacy and Safety Trial of Fedratinib in Subjects with DIPSS (Dynamic International Prognostic Scoring System)-Intermediate or High- Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF), or Post-Essential Thrombocythemia Myelofibrosis (post-ET MF) and Previously Treated with Ruxolitinib. The primary objective of the study is to evaluate ...
Assess the Safety Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib
The study will employ a standard 3+3 dose escalation design to determine maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), with additional subjects treated in a dose expansion cohort. The time period for collecting dose limiting toxicities (DLTs) is 1 cycle (21 days).
Azacitidine Venetoclax and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
PRIMARY OBJECTIVES: I. To determine the maximum-tolerated dose (MTD) of venetoclax in combination with azacitidine and pevonedistat in patients with previously untreated secondary acute myeloid leukemia (AML). (Phase I) II. To determine the efficacy of the combination regimen, as defined by the rate of complete response (CR) plus complete response ...
